Updated on 2025/10/23

写真a

 
TANAKA Hiroyoshi
 
Organization
Faculty of Medicine, Dentistry and Pharmaceutical Sciences Assistant Professor
Position
Assistant Professor
Profile

2013.3 東京大学 医学部 MD研究者育成プログラム(第2期)修了
2013.3 東京大学 医学部医学科 卒業、医師免許 取得
2013.4-2016.3 東京大学 大学院医学系研究科 病因・病理学専攻
2013.4-2016.3 武田科学振興財団 医学部博士課程奨学生
2016.4-現在 岡山大学 助教(現職)
2016.4-現在 国立病院機構 岡山医療センター 客員研究員
2019.6-現在 preLighter (HP: https://prelights.biologists.com/profiles/hytanaka/)
2019 Mansfield-PhRMA Research Scholar (7th cohort)
2019.7-現在 次世代医工学研究会 幹事
2024.7-現在 次世代医工学研究会 副幹事長
2024.9 岡山大学 大学院ヘルスシステム統合科学研究科 博士(統合科学)取得

External link

Degree

  • 博士(統合科学) ( 2024.9   岡山大学 )

  • 学士(医学) ( 2013.3   東京大学 )

Research Interests

  • Biomaterials

  • Nanomedicine

  • Fibrosis

  • Tumor biology

  • Vascular biology

Research Areas

  • Life Science / Cell biology

  • Nanotechnology/Materials / Nanobioscience

  • Life Science / Tumor biology

  • Life Science / Experimental pathology

Education

  • The University of Tokyo   医学系研究科   病因・病理学専攻 分子病理学

    - 2016

      More details

    Country: Japan

    researchmap

  • The University of Tokyo   医学部   医学科

    - 2013

      More details

    Country: Japan

    researchmap

Research History

  • Okayama University   学術研究院医歯薬学域   Assistant Professor

    2021.4

      More details

  • Okayama University   大学院医歯薬学総合研究科   Assistant Professor

    2016.4 - 2021.3

      More details

  • Assistant Professor,Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,Okayama University

    2016.4

      More details

Professional Memberships

 

Papers

  • Targeting ROCK2 improves macromolecular permeability in a 3D fibrotic pancreatic cancer microenvironment model Reviewed

    Hiroyoshi Y. Tanaka, Takuya Nakazawa, Takuya Miyazaki, Horacio Cabral, Atsushi Masamune, Mitsunobu R. Kano

    Journal of Controlled Release   369   283 - 295   2024.5

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Elsevier BV  

    DOI: 10.1016/j.jconrel.2024.03.041

    researchmap

  • Therapeutic Strategies to Overcome Fibrotic Barriers to Nanomedicine in the Pancreatic Tumor Microenvironment. Invited Reviewed International journal

    Hiroyoshi Y Tanaka, Takuya Nakazawa, Atsushi Enomoto, Atsushi Masamune, Mitsunobu R Kano

    Cancers   15 ( 3 )   2023.1

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    Pancreatic cancer is notorious for its dismal prognosis. The enhanced permeability and retention (EPR) effect theory posits that nanomedicines (therapeutics in the size range of approximately 10-200 nm) selectively accumulate in tumors. Nanomedicine has thus been suggested to be the "magic bullet"-both effective and safe-to treat pancreatic cancer. However, the densely fibrotic tumor microenvironment of pancreatic cancer impedes nanomedicine delivery. The EPR effect is thus insufficient to achieve a significant therapeutic effect. Intratumoral fibrosis is chiefly driven by aberrantly activated fibroblasts and the extracellular matrix (ECM) components secreted. Fibroblast and ECM abnormalities offer various potential targets for therapeutic intervention. In this review, we detail the diverse strategies being tested to overcome the fibrotic barriers to nanomedicine in pancreatic cancer. Strategies that target the fibrotic tissue/process are discussed first, which are followed by strategies to optimize nanomedicine design. We provide an overview of how a deeper understanding, increasingly at single-cell resolution, of fibroblast biology is revealing the complex role of the fibrotic stroma in pancreatic cancer pathogenesis and consider the therapeutic implications. Finally, we discuss critical gaps in our understanding and how we might better formulate strategies to successfully overcome the fibrotic barriers in pancreatic cancer.

    DOI: 10.3390/cancers15030724

    PubMed

    researchmap

  • Heterotypic 3D pancreatic cancer model with tunable proportion of fibrotic elements Reviewed International journal

    Hiroyoshi Y. Tanaka, Tsuyoshi Kurihara, Takuya Nakazawa, Michiya Matsusaki, Atsushi Masamune, Mitsunobu R. Kano

    Biomaterials   251   120077 - 120077   2020.8

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.biomaterials.2020.120077

    Scopus

    PubMed

    researchmap

  • Pancreatic stellate cells derived from human pancreatic cancer demonstrate aberrant SPARC-dependent ECM remodeling in 3D engineered fibrotic tissue of clinically relevant thickness Reviewed International journal

    Hiroyoshi Y. Tanaka, Kentaro Kitahara, Naoki Sasaki, Natsumi Nakao, Kae Sato, Hirokazu Narita, Hiroshi Shimoda, Michiya Matsusaki, Hiroshi Nishihara, Atsushi Masamune, Mitsunobu R. Kano

    Biomaterials   192   355 - 367   2019.2

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.biomaterials.2018.11.023

    Scopus

    PubMed

    researchmap

  • Stromal barriers to nanomedicine penetration in the pancreatic tumor microenvironment Invited Reviewed

    Hiroyoshi Y. Tanaka, Mitsunobu R. Kano

    Cancer Science   109 ( 7 )   2085 - 2092   2018.7

     More details

    Authorship:Lead author  

    DOI: 10.1111/cas.13630

    Scopus

    PubMed

    researchmap

  • Artificial Intelligence Approach in Machine Learning-Based Modeling and Networking of the Coronavirus Pathogenesis Pathway. Reviewed International journal

    Shihori Tanabe, Sabina Quader, Ryuichi Ono, Hiroyoshi Y Tanaka, Akihisa Yamamoto, Motohiro Kojima, Edward J Perkins, Horacio Cabral

    Current Issues in Molecular Biology   47 ( 6 )   2025.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The coronavirus pathogenesis pathway, which consists of severe acute respiratory syndrome (SARS) coronavirus infection and signaling pathways, including the interferon pathway, the transforming growth factor beta pathway, the mitogen-activated protein kinase pathway, the apoptosis pathway, and the inflammation pathway, is activated upon coronaviral infection. An artificial intelligence approach based on machine learning was utilized to develop models with images of the coronavirus pathogenesis pathway to predict the activation states. Data on coronaviral infection held in a database were analyzed with Ingenuity Pathway Analysis (IPA), a network pathway analysis tool. Data related to SARS coronavirus 2 (SARS-CoV-2) were extracted from more than 100,000 analyses and datasets in the IPA database. A total of 27 analyses, including nine analyses of SARS-CoV-2-infected human-induced pluripotent stem cells (iPSCs) and iPSC-derived cardiomyocytes and fibroblasts, and a total of 22 analyses of SARS-CoV-2-infected lung adenocarcinoma (LUAD), were identified as being related to "human" and "SARS coronavirus 2" in the database. The coronavirus pathogenesis pathway was activated in SARS-CoV-2-infected iPSC-derived cells and LUAD cells. A prediction model was developed in Python 3.11 using images of the coronavirus pathogenesis pathway under different conditions. The prediction model of activation states of the coronavirus pathogenesis pathway may aid in treatment identification.

    DOI: 10.3390/cimb47060466

    PubMed

    researchmap

  • がん微小環境における線維化とナノDDS Invited

    田中 啓祥, 狩野 光伸

    Drug Delivery System   36 ( 4 )   232 - 240   2021.9

     More details

    Authorship:Lead author   Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:日本DDS学会  

    researchmap

  • Modeling and analysis of disease microenvironments with 3D cell culture technology Invited Reviewed

    Hiroyoshi Y. Tanaka

    Yakugaku Zasshi   141 ( 5 )   647 - 653   2021.5

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (international conference proceedings)  

    DOI: 10.1248/yakushi.20-00219-4

    Scopus

    PubMed

    researchmap

  • 三次元培養技術によるがん微小環境のin vitroでの再現とDDS研究への応用 Invited

    田中 啓祥, 栗原 毅, 狩野 光伸

    Drug Delivery System   35 ( 5 )   445 - 447   2020.11

     More details

    Authorship:Lead author   Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:日本DDS学会  

    researchmap

  • Antibiotic prescriptions for Japanese outpatients with acute respiratory tract infections (2013–2015): A retrospective Observational Study Reviewed International journal

    Toshihiro Koyama, Hideharu Hagiya, Yusuke Teratani, Yasuhisa Tatebe, Ayako Ohshima, Mayu Adachi, Tomoko Funahashi, Yoshito Zamami, Hiroyoshi Y. Tanaka, Ken Tasaka, Kazuaki Shinomiya, Yoshihisa Kitamura, Toshiaki Sendo, Shiro Hinotsu, Mitsunobu R. Kano

    Journal of Infection and Chemotherapy   26 ( 7 )   660 - 666   2020.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jiac.2020.02.001

    Scopus

    PubMed

    researchmap

  • 3D in vitro Model of Vascular Medial Thickening in Pulmonary Arterial Hypertension Reviewed

    Chiharu Morii, Hiroyoshi Y. Tanaka, Yasuhisa Izushi, Natsumi Nakao, Masaya Yamamoto, Hiromi Matsubara, Mitsunobu R. Kano, Aiko Ogawa

    Frontiers in Bioengineering and Biotechnology   8   2020.5

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3389/fbioe.2020.00482

    Scopus

    researchmap

  • In vivo rendezvous of small nucleic acid drugs with charge-matched block catiomers to target cancers Reviewed International journal

    Sumiyo Watanabe, Kotaro Hayashi, Kazuko Toh, Hyun Jin Kim, Xueying Liu, Hiroyuki Chaya, Shigeto Fukushima, Keisuke Katsushima, Yutaka Kondo, Satoshi Uchida, Satomi Ogura, Takahiro Nomoto, Hiroyasu Takemoto, Horacio Cabral, Hiroaki Kinoh, Hiroyoshi Y. Tanaka, Mitsunobu R. Kano, Yu Matsumoto, Hiroshi Fukuhara, Shunya Uchida, Masaomi Nangaku, Kensuke Osada, Nobuhiro Nishiyama, Kanjiro Miyata, Kazunori Kataoka

    Nature Communications   10 ( 1 )   1894 - 1894   2019.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/s41467-019-09856-w

    Scopus

    PubMed

    researchmap

  • Oral anticoagulants usage in Japanese patients aged 18-74 years with non-valvular atrial fibrillation: A retrospective analysis based on insurance claims data Reviewed International journal

    Ayako Ohshima, Toshihiro Koyama, Aiko Ogawa, Yoshito Zamami, Hiroyoshi Y. Tanaka, Yoshihisa Kitamura, Toshiaki Sendo, Shiro Hinotsu, Michael W. Miller, Mitsunobu R. Kano

    Family Practice   36 ( 6 )   685 - 692   2019.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1093/fampra/cmz016

    Scopus

    PubMed

    researchmap

  • Pattern of antibiotic prescriptions for outpatients with acute respiratory tract infections in Japan, 2013-15: A retrospective observational study Reviewed

    Yusuke Teratani, Hideharu Hagiya, Toshihiro Koyama, Mayu Adachi, Ayako Ohshima, Yoshito Zamami, Hiroyoshi Y. Tanaka, Yasuhisa Tatebe, Ken Tasaka, Naoko Mikami, Kazuaki Shinomiya, Yoshihisa Kitamura, Mitsunobu R. Kano, Shiro Hinotsu, Toshiaki Sendo

    Family Practice   36 ( 4 )   402 - 409   2019.8

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1093/fampra/cmy094

    Scopus

    PubMed

    researchmap

  • Stroma Nanotechnologyを応用したDrug Delivery System Invited

    田中 啓祥, 狩野 光伸

    肝・胆・膵   75 ( 4 )   805 - 809   2017.10

     More details

    Authorship:Lead author   Language:Japanese   Publisher:(株)アークメディア  

    J-GLOBAL

    researchmap

  • Desmoplastic Reaction in 3D-Pancreatic Cancer Tissues Suppresses Molecular Permeability Reviewed International journal

    Michiya Matsusaki, Misaki Komeda, Simona Mura, Hiroyoshi Y. Tanaka, Mitsunobu R. Kano, Patrick Couvreur, Mitsuru Akashi

    Advanced Healthcare Materials   6 ( 15 )   2017.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/adhm.201700057

    Web of Science

    Scopus

    PubMed

    researchmap

  • Regulation of endothelial Fas expression as a mechanism of promotion of vascular integrity by mural cells in tumors Reviewed International journal

    Ryosuke Kamei, Hiroyoshi Y. Tanaka, Takao Kawano, Chiharu Morii, Sayaka Tanaka, Hiroshi Nishihara, Caname Iwata, Mitsunobu R. Kano

    Cancer Science   108 ( 5 )   1080 - 1088   2017.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Cancer Science  

    DOI: 10.1111/cas.13216

    Scopus

    PubMed

    researchmap

  • Increased fibrosis and impaired intratumoral accumulation of macromolecules in a murine model of pancreatic cancer co-administered with FGF-2 Reviewed International journal

    Satoshi Sakai, Caname Iwata, Hiroyoshi Y. Tanaka, Horacio Cabral, Yasuyuki Morishita, Kohei Miyazono, Mitsunobu R. Kano

    Journal of Controlled Release   230   109 - 115   2016.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jconrel.2016.04.007

    Web of Science

    Scopus

    PubMed

    researchmap

  • Secretions from placenta, after hypoxia/reoxygenation, can damage developing neurones of brain under experimental conditions Reviewed International journal

    Daniel J. Curtis, Aman Sood, Tom J. Phillips, Akihiro Nishiguchi, Veron H.L. Leinster, Christopher Coyle, Lizeth Lacharme-Lora, Oliver Beaumont, Helena Kemp, Roberta Goodall, Leila Cornes, Michele Giugliano, Rocco A. Barone, Michiya Matsusaki, Mitsuru Akashi, Hiroyoshi Y. Tanaka, Mitsunobu Kano, Jennifer McGarvey, Nagaraj D. Halemani, Katja Simon, Robert Keehan, William Ind, Tracey Masters, Simon Grant, Sharan Athwal, Gavin Collett, Dionne Tannetta, Ian L. Sargent, Emma Scull-Brown, Xun Liu, Kristian Aquilina, Nicki Cohen, Jon D. Lane, Marianne Thoresen, Jon Hanley, Andrew Randall, C. Patrick Case

    Experimental Neurology   261   386 - 395   2014.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.expneurol.2014.05.003

    Web of Science

    Scopus

    PubMed

    researchmap

▼display all

Books

  • Cancer Drug Delivery Systems Based on the Tumor Microenvironment

    ( Role: Contributor ,  Chapter 4 Stromal barriers within the tumor microenvironment and obstacles to nanomedicine)

    Springer Nature  2019 

     More details

  • DDS先端技術の製材への応用開発(共著)

    技術情報協会  2017  ( ISBN:9784861046

     More details

MISC

  • 難治性呼吸器疾患・肺高血圧症に関する調査研究 三次元培養技術による肺動脈性肺高血圧症の新規治療薬探索

    小川愛子, 森井千春, 田中啓祥, 出石恭久, 中尾なつみ, 山本雅哉, 松原広己, 狩野光伸

    難治性呼吸器疾患・肺高血圧症に関する調査研究 令和2年度 研究報告書(Web)   2021

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

Presentations

  • マクロピノサイトーシスは膵癌関連膵星細胞の腫瘍融解ウイルスへの感受性を増強する

    西山 岳芳, 田澤 大, 永井 康雄, 庄司 良平, 菊地 覚次, 黒田 新士, 大原 利章, 野間 和広, 田中 啓祥, 狩野 光伸, 浦田 泰生, 香川 俊輔, 藤原 俊義

    日本癌治療学会学術集会抄録集  2024.10  (一社)日本癌治療学会

     More details

    Event date: 2024.10

    Language:English  

    researchmap

  • 積層培養技術による肺動脈壁の立体培養モデルの開発と肺高血圧症の病態進展機序の解析への応用

    和田 笑里, 木山 和子, 松原 広己, 狩野 光伸, 田中 啓祥

    国立病院総合医学会講演抄録集  2023.10  国立病院総合医学会

     More details

    Event date: 2023.10

    Language:Japanese  

    researchmap

  • 慢性血栓塞栓性肺高血圧症(CTEPH)における器質化血栓の形成機序の解析および標的化法の開発

    桐石 奈月, 木山 和子, 松原 広己, 田中 啓祥, 狩野 光伸

    国立病院総合医学会講演抄録集  2023.10  国立病院総合医学会

     More details

    Event date: 2023.10

    Language:Japanese  

    researchmap

  • 肺動脈性肺高血圧症において肺動脈平滑筋細胞の過剰増殖に関わるPDGFシグナル経路の体系的解析

    中澤 拓也, 橋田 真穂, 木山 和子, 松原 広己, 狩野 光伸, 田中 啓祥

    国立病院総合医学会講演抄録集  2023.10  国立病院総合医学会

     More details

    Event date: 2023.10

    Language:Japanese  

    researchmap

  • 慢性血栓塞栓性肺高血圧症に対するバルーン肺動脈形成術後の病変部自然拡張の機序

    木山 和子, 田中 啓祥, 小川 愛子, 松原 広己

    国立病院総合医学会講演抄録集  2023.10  国立病院総合医学会

     More details

    Event date: 2023.10

    Language:Japanese  

    researchmap

  • 膵がん線維化障壁をTRPP3阻害により克服するナノ薬剤送達戦略の開発

    中澤 拓也, 田中 啓祥, 狩野 光伸

    日本DDS学会学術集会プログラム予稿集  2023.7  日本DDS学会

     More details

    Event date: 2023.7

    Language:Japanese  

    researchmap

  • 多様な臓器から考える線維化治療への最先端アプローチ 三次元培養法による膵がん線維化組織のモデル化および筋線維芽細胞分化機序の解析

    中澤 拓也, 田中 啓祥, 狩野 光伸

    日本薬学会年会要旨集  2022.3  (公社)日本薬学会

     More details

    Event date: 2022.3

    Language:Japanese  

    researchmap

  • 膵がん線維化障壁をマクロピノサイトーシス経路阻害により克服するナノ薬剤送達戦略の開発

    中澤拓也, 田中啓祥, 狩野光伸

    日本DDS学会学術集会プログラム予稿集  2022 

     More details

    Event date: 2022

    researchmap

  • 細胞外基質シグナリングの標的化により膵がん線維化障壁を克服するナノ薬剤送達戦略の開発

    田中啓祥, 田中啓祥, 瀬野尾祐, 狩野光伸, 狩野光伸

    日本DDS学会学術集会プログラム予稿集  2022 

     More details

    Event date: 2022

    researchmap

  • 線維化量を制御可能なヒト膵がん微小環境の三次元培養モデルの確立・解析とナノDDS研究への応用

    田中 啓祥, 狩野 光伸

    日本DDS学会学術集会プログラム予稿集  2021.6  日本DDS学会

     More details

    Event date: 2021.6

    Language:Japanese  

    researchmap

  • p53発現による線維性微小環境の再プログラム化は膵臓癌における腫瘍融解ウイルス療法の治療効果を増強する

    西山岳芳, 田澤大, 田澤大, 梶原義典, 庄司良平, 永井康雄, 菊地覚次, 黒田新士, 黒田新士, 野間和広, 吉田龍一, 西崎正彦, 田中啓祥, 狩野光伸, 浦田泰生, 香川俊輔, 藤原俊義

    日本癌学会学術総会抄録集(Web)  2021 

     More details

    Event date: 2021

    researchmap

  • Heterotypic 3D Culture Model of the Pancreatic Cancer Microenvironment with a Tunable Proportion of Fibrotic Elements

    Hiroyoshi Y. Tanaka, Atsushi Masamune, Mitsunobu R. Kano

    2020.10.3  (一社)日本癌学会

     More details

    Event date: 2020.10.1 - 2020.10.3

    Language:English   Presentation type:Oral presentation (general)  

    researchmap

  • 膵臓がん線維化組織の3D培養モデルを利用したナノ薬剤送達効率の解析

    田中 啓祥, 狩野 光伸

    日本DDS学会学術集会プログラム予稿集  2020.8  日本DDS学会

     More details

    Event date: 2020.8

    Language:Japanese  

    researchmap

  • 次世代医工薬学に基づく"細胞編集"-バイオマテリアルを活かした細胞機能制御- 立体培養法を利用した疾患微小環境モデルの開発と病態解析

    田中 啓祥

    日本薬学会年会要旨集  2020.3  (公社)日本薬学会

     More details

    Event date: 2020.3

    Language:Japanese  

    researchmap

  • The use of 3D cell culture technology to model the tissue microenvironment and its applications in studying disease

    田中啓祥, 狩野光伸, 狩野光伸

    日本化学会春季年会講演予稿集(CD-ROM)  2020 

     More details

    Event date: 2020

    researchmap

  • ヒト膵がん由来膵星状細胞を用いた三次元膵がん線維化モデルの構築ならびに異常ECM改築の機序の解析(Pancreatic stellate cells from human pancreatic cancer show aberrant ECM remodeling in 3D engineered fibrotic tissue)

    田中 啓祥, 西原 広史, 正宗 淳, 狩野 光伸

    日本癌学会総会記事  2019.9  日本癌学会

     More details

    Event date: 2019.9

    Language:English  

    researchmap

  • Pancreatic stellate cells from human pancreatic cancer show aberrant ECM remodeling in 3D engineered fibrotic tissue

    田中啓祥, 西原広史, 正宗淳, 狩野光伸, 狩野光伸

    日本癌学会学術総会抄録集(Web)  2019 

     More details

    Event date: 2019

    researchmap

  • Developing experimental models to analyze the behavior of Nano-DDSs within biological systems

    Mitsunobu R Kano, Hiroyoshi Y Tanaka

    Cancer science  2018 

     More details

    Event date: 2018

    researchmap

  • 膵がんにおける組織構築の特徴とナノ薬剤の活用法を考える

    狩野光伸, 狩野光伸, 田中啓祥

    日本DDS学会学術集会プログラム予稿集  2018 

     More details

    Event date: 2018

    researchmap

  • 膠芽腫幹細胞様細胞はFGF/FGFRシグナルを介し腫瘍血管の漏出性を減少させる

    田中 啓祥, 狩野 光伸

    日本癌学会総会記事  2016.10  (一社)日本癌学会

     More details

    Event date: 2016.10

    Language:English  

    researchmap

  • 膵臓がんにおいてナノ薬剤送達の障壁となる線維化組織の立体培養法によるモデル化および解析

    田中 啓祥, 狩野 光伸

    日本DDS学会学術集会プログラム予稿集  2019.6 

     More details

    Language:Japanese  

    researchmap

  • 疾患環境の理解とDDS 膵がんにおける組織構築の特徴とナノ薬剤の活用法を考える

    狩野 光伸, 田中 啓祥

    日本DDS学会学術集会プログラム予稿集  2018.5 

     More details

    Language:Japanese  

    researchmap

  • バイオマテリアルによるがん研究の展開(学際ネットワーク) ナノDDS研究のためのモデル開発

    狩野 光伸, 田中 啓祥

    日本癌学会総会記事  2017.9 

     More details

    Language:English  

    researchmap

  • 肺高血圧症症例由来の肺血管細胞を用いた血管モデルの構築

    久永 なつみ, 小川 愛子, 田中 啓祥, 狩野 光伸, 松原 広己

    血管  2017.1 

     More details

    Language:Japanese  

    researchmap

  • Glioblastoma Stem-Like Cells Promote Barrier Integrity of Tumor Vasculature via FGF/FGFR Signaling

    The 75th Annual Meeting of the Japanese Cancer Association  2016 

     More details

▼display all

Awards

  • The Young Investigator Award of the Japanese Cancer Association

    2025.9   Japanese Cancer Association  

     More details

  • 優秀演題賞Nanoscale Horizons賞

    2025.6   第41回日本DDS学会学術集会   NUAK2 inhibition enhances macromolecular delivery in a 3D model of the fibrotic pancreatic tumor microenvironment

     More details

  • 積層培養技術による膵がん微小環境のin vitroでの再構成と病態生理学的解析

    2025.5  

     More details

  • 優秀発表賞

    2015.1   第三回日本バイオマテリアル学会中四国シンポジウム   膠芽腫における血管透過性およびその制御機序の解析

     More details

    Country:Japan

    researchmap

Research Projects

  • KRAS/MAPKシグナル遮断への膵がんの獲得耐性のSRC family kinase標的化による克服

    2024.05 - 2025.09

    日本応用酵素協会  2024年度酵素研究助成 

      More details

    Authorship:Principal investigator 

    researchmap

  • Development of therapeutic strategies to overcome fibrotic barriers to nanomedicine in pancreatic cancer via targeting of extracellular matrix signaling

    Grant number:23K06279  2023.04 - 2026.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    田中 啓祥, 正宗 淳

      More details

    Grant amount:\4680000 ( Direct expense: \3600000 、 Indirect expense:\1080000 )

    researchmap

  • 膵がんにおける線維化の治療的制御に基づくナノ薬剤送達戦略の開発

    2022.04 - 2024.03

    薬学研究奨励財団  第42回(2021年度)研究助成 

      More details

    Authorship:Principal investigator 

    researchmap

  • 膵がんにおける線維化障壁を克服するナノメディシン戦略の開発

    2022.04 - 2023.03

    稲盛財団  2022年度研究助成 

      More details

    Authorship:Principal investigator 

    researchmap

  • 膵がん微小環境の立体培養モデルを活用したRAS/MAPK経路標的薬への獲得耐性出現機序の解明

    2021.11 - 2022.11

    ホクト生物科学振興財団  2021年度 ホクト生物科学振興財団助成 

      More details

    Authorship:Principal investigator 

    researchmap

  • 結合組織病(膠原病)に伴う肺動脈性肺高血圧症患者由来細胞を用いた治療抵抗性メカニズムの解析と新規治療法の開発

    2021.10 - 2022.06

    横山臨床薬理研究助成基金  令和3年度 萌芽的研究助成 

      More details

    Authorship:Principal investigator 

    researchmap

  • 膵がん線維化間質におけるECM異常構築の治療的リモデリングによる効果的なナノメディシン戦略の開発

    2021.09 - 2022.03

    両備檉園記念財団  2021年度(第43回)研究助成 

      More details

    Authorship:Principal investigator 

    researchmap

  • The use of 3D cell culture to study the mechanisms underlying aberrant ECM remodeling in pancreatic cancer stroma

    Grant number:20K16989  2020.04 - 2023.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Early-Career Scientists  Grant-in-Aid for Early-Career Scientists

    田中 啓祥

      More details

    Grant amount:\4160000 ( Direct expense: \3200000 、 Indirect expense:\960000 )

    本研究の目的は、膵がん間質の線維化組織における線維芽細胞ならびに細胞外基質(ECM)線維の「異常配向」獲得の分子機序を解明することである。膵がんの特徴である間質の顕著な線維化組織において、線維芽細胞ならびにCollagenやFibronectinなどのECM線維は異常な配向・構築を示す。こうしたECM異常が、膵がん組織の硬化を来し、病態進展および治療抵抗性獲得に寄与することが明らかとなってきている。しかし、細胞ならびにECM線維の異常配向の獲得機序は、従来の実験モデルでは詳細な分子機序の解析が困難であり、詳細が不明である。これまで本研究では、研究代表者が独自に確立した立体培養法を応用したin vitro線維化モデル(Biomaterials 2019)を用い、ECM要素の配向獲得に寄与するシグナル経路の解析を行ってきた。さらに、当初計画における膵がん由来線維芽細胞単独で構築したin vitro線維化モデルの利用のみならず、膵がん細胞と正常線維芽細胞との三次元共培養系をも確立し、正常な線維芽細胞が膵がん細胞との共培養を通じ異常ECM構築を獲得する過程のin vitroでの再現にも成功してきた(Biomaterials 2020)。令和三年度は、ECMの異常配向獲得に関わるECM受容体の探索を行い、さらに細胞内シグナル伝達機序の解析を進めた。また、こうして明らかとなってきた異常シグナル伝達を標的化することで、線維化組織中の薬物送達を改善しうることを見出した(manuscript in preparation)。

    researchmap

  • 3D培養法による肺動脈中膜肥厚モデルを用いた炎症誘導とPAH病態進展の機序解析

    2020.04 - 2021.03

    グラクソ・スミスクライン株式会社  2019年度 GSKジャパン研究助成 

      More details

    Authorship:Principal investigator 

    researchmap

  • 膵がんの難治性を克服するナノ薬剤治療の確立へ向けた間質バリアの治療的制御法の開発

    2020.04 - 2021.03

    山陽放送学術文化財団  第57回(令和元年度)研究助成 

      More details

    Authorship:Principal investigator 

    researchmap

  • 膵がん間質のECM構築異常を標的としたナノ薬剤送達改善のための間質改築戦略の開発

    2019.12 - 2020.09

    日本膵臓病研究財団  第27回(2019年度)膵臓病研究奨励賞 

      More details

    Authorship:Principal investigator 

    researchmap

  • Modeling and analysis of the pancreatic tumor microenvironment using 3D cell culture techniques

    2019 - 2020

    The KAWASAKI Foundation for Medical Science and Medical Welfare  令和元年度 川崎医学・医療福祉学振興会 教育研究助成 

    Hiroyoshi Y. Tanaka

      More details

    Authorship:Principal investigator 

    researchmap

▼display all

 

Class subject in charge

  • Practice in Clinical and Biopharmaceutical Sciences (2025academic year) Third semester  - その他5~9

  • Practice in Clinical and Biopharmaceutical Sciences (2025academic year) Third semester  - その他5~9

  • Practice in Clinical and Biopharmaceutical Sciences (2025academic year) Third semester  - その他5~9

  • Practice in Clinical and Biopharmaceutical Sciences (2025academic year) Third semester  - その他5~9

  • Basic Practice in Pharmaceutical Sciences (2025academic year) 1st semester  - その他5~9

  • Basic Practice in Pharmaceutical Sciences (2025academic year) 1st semester  - その他5~9

  • Basic Practice in Pharmaceutical Sciences (2025academic year) 1st semester  - その他5~9

  • Basic Practice in Pharmaceutical Sciences (2025academic year) 1st semester  - その他5~9

  • Pharmacotherapeutic 1 (2025academic year) 1st semester  - 水1~2

  • Pharmacotherapeutic 1 (2025academic year) 1st semester  - 水1~2

  • Pharmacotherapeutic 2 (2025academic year) Second semester  - 水1~2

  • Pharmacotherapeutic 2 (2025academic year) Second semester  - 水1~2

  • Pharmacotherapeutic 3 (2025academic year) 1st semester  - 水3~4

  • Pharmacotherapeutic 3 (2025academic year) 1st semester  - 水3~4

  • Pharmacotherapeutic 4 (2025academic year) Second semester  - 水3~4

  • Pharmacotherapeutic 4 (2025academic year) Second semester  - 水3~4

  • Pharmacotherapeutic A (2025academic year) 1st and 2nd semester  - 水1~2

  • Pharmacotherapeutic A (2025academic year) 1st and 2nd semester  - 水1~2

  • Pharmacotherapeutic B (2025academic year) 1st and 2nd semester  - 水3~4

  • Pharmacotherapeutic B (2025academic year) 1st and 2nd semester  - 水3~4

  • Practice in Clinical and Biopharmaceutical Sciences (2024academic year) Third semester  - その他5~9

  • Practice in Clinical and Biopharmaceutical Sciences (2024academic year) Third semester  - その他5~9

  • Practice in Clinical and Biopharmaceutical Sciences (2024academic year) Third semester  - その他5~9

  • Practice in Clinical and Biopharmaceutical Sciences (2024academic year) Third semester  - その他5~9

  • Basic Practice in Pharmaceutical Sciences (2024academic year) 1st semester  - その他5~9

  • Basic Practice in Pharmaceutical Sciences (2024academic year) 1st semester  - その他5~9

  • Basic Practice in Pharmaceutical Sciences (2024academic year) 1st semester  - その他5~9

  • Basic Practice in Pharmaceutical Sciences (2024academic year) 1st semester  - その他5~9

  • Pharmacotherapeutic 1 (2024academic year) 1st semester  - 水1~2

  • Pharmacotherapeutic 1 (2024academic year) 1st semester  - 水1~2

  • Pharmacotherapeutic 2 (2024academic year) Second semester  - 水1~2

  • Pharmacotherapeutic 2 (2024academic year) Second semester  - 水1~2

  • Pharmacotherapeutic 3 (2024academic year) 1st semester  - 水3~4

  • Pharmacotherapeutic 3 (2024academic year) 1st semester  - 水3~4

  • Pharmacotherapeutic 4 (2024academic year) Second semester  - 水3~4

  • Pharmacotherapeutic 4 (2024academic year) Second semester  - 水3~4

  • Pharmacotherapeutic A (2024academic year) 1st and 2nd semester  - 水1~2

  • Pharmacotherapeutic A (2024academic year) 1st and 2nd semester  - 水1~2

  • Pharmacotherapeutic B (2024academic year) 1st and 2nd semester  - 水3~4

  • Pharmacotherapeutic B (2024academic year) 1st and 2nd semester  - 水3~4

  • Practice in Clinical and Biopharmaceutical Sciences (2023academic year) Third semester  - その他5~9

  • Practice in Clinical and Biopharmaceutical Sciences (2023academic year) Third semester  - その他5~9

  • Practice in Clinical and Biopharmaceutical Sciences (2023academic year) Third semester  - その他5~9

  • Practice in Clinical and Biopharmaceutical Sciences (2023academic year) Third semester  - その他5~9

  • Basic Practice in Pharmaceutical Sciences (2023academic year) 1st semester  - その他5~9

  • Basic Practice in Pharmaceutical Sciences (2023academic year) 1st semester  - その他5~9

  • Basic Practice in Pharmaceutical Sciences (2023academic year) 1st semester  - その他5~9

  • Basic Practice in Pharmaceutical Sciences (2023academic year) 1st semester  - その他5~9

  • Pharmacotherapeutic 1 (2023academic year) 1st semester  - 水1~2

  • Pharmacotherapeutic 1 (2023academic year) 1st semester  - 水1~2

  • Pharmacotherapeutic 2 (2023academic year) Second semester  - 水1~2

  • Pharmacotherapeutic 2 (2023academic year) Second semester  - 水1~2

  • Pharmacotherapeutic 3 (2023academic year) 1st semester  - 水3~4

  • Pharmacotherapeutic 3 (2023academic year) 1st semester  - 水3~4

  • Pharmacotherapeutic 4 (2023academic year) Second semester  - 水3~4

  • Pharmacotherapeutic 4 (2023academic year) Second semester  - 水3~4

  • Pharmacotherapeutic A (2023academic year) 1st and 2nd semester  - 水1~2

  • Pharmacotherapeutic A (2023academic year) 1st and 2nd semester  - 水1~2

  • Pharmacotherapeutic B (2023academic year) 1st and 2nd semester  - 水3~4

  • Pharmacotherapeutic B (2023academic year) 1st and 2nd semester  - 水3~4

  • Practice in Clinical and Biopharmaceutical Sciences (2022academic year) Third semester  - その他5~9

  • Practice in Clinical and Biopharmaceutical Sciences (2022academic year) Third semester  - その他5~9

  • Basic Practice in Pharmaceutical Sciences (2022academic year) 1st semester  - その他5~9

  • Basic Practice in Pharmaceutical Sciences (2022academic year) 1st semester  - その他5~9

  • Pharmacotherapeutic 1 (2022academic year) 1st semester  - 水1~2

  • Pharmacotherapeutic 1 (2022academic year) 1st semester  - 水1~2

  • Pharmacotherapeutic 2 (2022academic year) Second semester  - 水1~2

  • Pharmacotherapeutic 2 (2022academic year) Second semester  - 水1~2

  • Pharmacotherapeutic 3 (2022academic year) 1st semester  - 水3~4

  • Pharmacotherapeutic 3 (2022academic year) 1st semester  - 水3~4

  • Pharmacotherapeutic 4 (2022academic year) Second semester  - 水3~4

  • Pharmacotherapeutic 4 (2022academic year) Second semester  - 水3~4

  • Pharmacotherapeutic I (2022academic year) 1st and 2nd semester  - 水1~2

  • Pharmacotherapeutic II (2022academic year) 1st and 2nd semester  - 水3~4

  • Basic Practice in Pharmaceutical Sciences (2021academic year) 1-3 semesters  - その他6~9

  • Basic Practice in Pharmaceutical Sciences (2021academic year) 1-3 semesters  - その他6~9

  • Practice in Fundamental Pharmaceutical Sciences III (2021academic year) Second semester  - その他6~9

  • Practice in Fundamental Pharmaceutical Sciences III (2021academic year) Second semester  - その他6~9

  • Practice in Fundamental Pharmaceutical Sciences III (2021academic year) Second semester  - その他6~9

  • Practice in Fundamental Pharmaceutical Sciences III (2021academic year) Second semester  - その他6~9

  • Pharmacotherapeutic 1 (2021academic year) 1st semester  - 水1~2

  • Pharmacotherapeutic 1 (2021academic year) 1st semester  - 水1~2

  • Pharmacotherapeutic 2 (2021academic year) Second semester  - 水1~2

  • Pharmacotherapeutic 2 (2021academic year) Second semester  - 水1~2

  • Pharmacotherapeutic 3 (2021academic year) 1st semester  - 水3~4

  • Pharmacotherapeutic 3 (2021academic year) 1st semester  - 水3~4

  • Pharmacotherapeutic 4 (2021academic year) Second semester  - 水3~4

  • Pharmacotherapeutic 4 (2021academic year) Second semester  - 水3~4

  • Basic Practice in Pharmaceutical Sciences (2020academic year) special  - その他

  • Basic Practice in Pharmaceutical Sciences (2020academic year) special  - その他

  • Practice in Fundamental Pharmaceutical Sciences III (2020academic year) Second semester  - その他

  • Practice in Fundamental Pharmaceutical Sciences III (2020academic year) Second semester  - その他

  • Pharmacotherapeutic 1 (2020academic year) 1st semester  - 水1,水2

  • Pharmacotherapeutic 1 (2020academic year) 1st semester  - 水1,水2

  • Pharmacotherapeutic 2 (2020academic year) Second semester  - 水1,水2

  • Pharmacotherapeutic 2 (2020academic year) Second semester  - 水1,水2

  • Pharmacotherapeutic 3 (2020academic year) 1st semester  - 水3,水4

  • Pharmacotherapeutic 3 (2020academic year) 1st semester  - 水3,水4

  • Pharmacotherapeutic 4 (2020academic year) Second semester  - 水3,水4

  • Pharmacotherapeutic 4 (2020academic year) Second semester  - 水3,水4

  • Pharmacotherapeutic I (2020academic year) 1st and 2nd semester  - 水1,水2

  • Pharmacotherapeutic II (2020academic year) 1st and 2nd semester  - 水3,水4

▼display all